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Abstract
Background: Acute aortic dissection (AAD) is a life-threatening condition with high mortality and a relatively unclariﬁ  ed 
pathophysiological mechanism. Although differentially expressed genes in AAD have been recognized, interactions between 
these genes remain poorly deﬁ  ned. This study was conducted to gain a better understanding of the molecular mechanisms 
underlying AAD and to support the future development of a clinical test for monitoring patients at high risk.
Materials and Methods: Aortic tissue was collected from 19 patients with AAD (mean age 61.7 ± 13.1 years), and 
from eight other patients (mean age 32.9 ± 12.2 years) who carried the mutated gene for Marfan syndrome (MS). Six 
patients (mean age 56.7 ± 12.3 years) served as the control group. The PIQOR
TM Immunology microarray with 1076 
probes in quadruplicates was utilized; the differentially expressed genes were analysed in a MedScan search using 
PathwayAssist software. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and protein analysis 
were performed.
Results: Interactions of MS ﬁ  brillin-1 (FBN1) in the MedScan pathway analysis showed four genes, ﬁ  bulin-1 (FBLN1), 
ﬁ  bulin-2 (FBLN2), decorin (DCN) and microﬁ  brillar associated protein 5 (MFAP5), which were differentially expressed 
in all tissue from AAD. The validation of these genes by qRT-PCR revealed a minimum of three-fold downregulation of 
FBLN1 (0.5 ± 0.4 vs. 6.1 ± 2.3 fold, p = 0.003) and of DCN (2.5 ± 1.0 vs. 8.5 ± 4.7 fold, p = 0.04) in AAD compared to 
MS and control samples.
Conclusions: Downregulation of ﬁ  brillin-1 (FBN1) may weaken extracellular components in the aorta and/or interfer with 
the transmission of cellular signals and eventually cause AAD. Additional research on these four identiﬁ  ed genes can be a 
starting point to develop a diagnostic tool.
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Introduction
Acute aortic dissection (AAD) is a life-threatening clinical entity requiring urgent surgical intervention. 
The peak incidence of aortic dissection is reported to occur in the sixth and seventh decades of life with 
2000 new cases per year in North America and 3000 in Europe.
1,2
The initiating event is an intimal tear due to congenital defects of the aortic wall, such as in Marfan 
syndrome (MS), Ehlers–Danlos syndrome (a heterogeneous group connective tissue disorders), idiopathic 
Erdheim Gsell medial necrosis, bicuspid aortic valve (the most common congenital heart disease), or 
even acquired intima damage caused by hypertension, thoracic trauma or other unknown mechanism.
3–5 
Subintima or media necrosis results in intimal tear, which eventually allows blood to enter into the 
aortic wall, thus leading to separation of the aortic wall layers and hence to a rapid propagation of the 
aortic dissection. The separation of the media and the adventitia layers of the aortic wall may lead to 
malperfusion of numerous organs with devastating complications.
2,6
An important clinical fact is that aortic dissections occur in both aneurysmatic expanded calibre as 
well as in normal calibre of the aorta. The most feared complication of aortic dissection is its outward 
rupture, which is associated with high mortality.
7 The surgical treatment depends on the location of the 
initial tear and on the longitudinal propagation of the dissection. To describe dissections various 82
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classifications have been proposed, with the 
DeBakey and the Stanford classiﬁ  cation more 
often used.
8,9
When the ascending aorta is affected (Stanford 
type A), the mortality of untreated patients is about 
36%–72% within the ﬁ  rst 48 hours and 62%–91% 
within the ﬁ  rst week.
10–13 Chest pain and other 
symptoms of ADD are often confused with those 
of cardiac infarction, thus complicating the diag-
nosis and delaying the treatment of AAD. There-
fore, a better understanding of the molecular 
mechanisms underlying AAD can be the ﬁ  rst step 
to supporting the future development of a rapid 
test for monitoring patients at high risk.
Questions about the underlying mechanisms in 
the aorta that make it more prone to be dissected 
and why many patients without gene defects on 
ﬁ  brillin-1 (FBN1) can be at high risk of develop-
ing AAD remain unanswered. The aim of this study 
was to investigate whether aortic tissue from 
patients with AAD presents signiﬁ  cant similari-
ties in their gene expression patterns and to 
compare these ﬁ  ndings with those from known 
MS. Using pathway analysis, the analysis of rela-
tionships between genes/proteins and the processes 
or diseases in which these genes/proteins are 
involved, was used to show which of the differen-
tially expressed genes in AAD can interact with 
MS FBN1.
Materials and Methods
The study protocol was approved by the institu-
tional ethics committee and written informed 
consent from all patients was obtained. In cases of 
ascending aorta replacement in patients with type A 
aortic dissection (AAD) or with Marfan syndrome 
(MS) without acute dissection, diseased aortic 
tissue was collected during surgery and immediately 
frozen in liquid nitrogen then used later for gene 
expression and protein analysis. To minimize the 
impact of age differences between patients with 
AAD and MS on the conﬁ  dence interval, additional 
tissue was taken during valve replacement surgery 
(Ross procedure, normal aorta and aortic valve) 
from six patients and used as control. Patients’ 
demographics are shown in Table 1.
Patients and Work Program
Samples were collected from whole aorta of 
19 patients with AAD (dissection type A, mean 
age 61.7 ± 13.1 years), eight patients with pheno-
typic features of MS who demonstrated fibrillin-1 
gene mutation (mean age 32.9 ± 12.2 years). In 
addition, aortic wall tissue samples taken during 
Ross procedure in cases of normal aorta (aortic 
diameter   37 mm) and without malformation 
of the aortic valve from six patients (mean age 
56.7 ± 12.3) were used as control. 5 ml EDTA 
venous blood for screening of mutations on 
fibrillin-1 gene were collected. Microarrays were 
hybridized to detect differentially expressed 
genes between patients with MS (labeled with 
Cy3) and patients with AAD (labeled with Cy5). 
The differentially generated genes of interest 
from these microarray results were validated for 
all patients of this study in the quantitative 
reverse transcription-polymerase chain reaction 
(qRT-PCR). Protein anlaysis was also performed 
for the most signiﬁ  cantly expressed genes.
RNA extraction
Total RNA was isolated using standard RNA 
purification protocols (Trizol; Sigma Aldrich, 
Germany). The integrity of total RNAs was 
checked via the Bioanalyzer 2100 system (Agilent 
Technologies). The peak areas of 28 S and 18 S 
RNA of every sample was determined and the ratio 
of 28 S/18 S calculated.
RNA ampliﬁ  cation and labelling
For hybridizations on PIQOR
TM microarrays, linear 
amplification of RNA was performed using a 
modified methodology described elsewhere.
14 
Table 1. Patients’ demographics.
Deﬁ  nition N Age (Y) BMI (Kg/m
2) LDH (U/L)
AAD 19 61.7 ± 13.1 27.0 ± 3.0 162.7 ± 60.6
MS 8 32.9 ± 12.2 23.0 ± 3.5 213 ± 155.8
C6 56.7 ± 12.3 28.3 ± 3.3 210.0 ± 67.3
Abbreviations: AAD, acute aortic dissection; MS, marfan syndrome; C, further control without dilation of the aorta.83
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Ampliﬁ  ed RNA (aRNA) samples were quantiﬁ  ed 
by spectrophotometry and the quality of the 
samples was proofed by gel electrophoresis 
(Bioanalyser 2001; Agilent). One microgram of 
aRNA from diseased tissue of AAD versus tissue 
of MS was labeled by reverse transcription with 
Cy5 and Cy3 ﬂ  uorescence, respectively. According 
to this study design, samples from normal aortic 
tissue were labeled by reverse transcription with 
Cy5. Labeled samples were then hybridized on 
PIQOR
TM Immunology microarrays.
Bioinformatics service: Re-calculation 
of new expression ratios based 
on a new reference 
In all microarray experiments the samples obtained 
from MS had been used as reference. To be able 
to compare all expression values with another 
control of normal aortic tissue, we labeled by 
reverse transcription every new reference with Cy5 
and hybridized against the common MS. We per-
formed in ﬁ  rst microarray experiments compared 
AAD against MS the expression ratios of these 
experiments were set against the expression ratio 
of second microarray experiments compared nor-
mal aortic tissue against MS.
Microarray production
Microarray production was performed as described 
previously.
15 Brieﬂ  y, prespeciﬁ  ed 200–400-bp frag-
ments of selected cDNAs were generated by RT-PCR 
(Superscript
TMII; Invitrogen, Groningen, The Neth-
erlands), cloned into pGEM
®-T Vector (Promega, 
Mannheim, Germany) and sequence-verified.
16 
Ampliﬁ  ed inserts (Taq PCR Master Mix; Qiagen) 
were puriﬁ  ed (Qiaquick 96 PCR BioRobot Kit; 
Qiagen), checked on an agarose gel, and spotted four 
times each (0.2 ng) on treated glass slides.
Array hybridization and data analysis
Hybridization, scanning and data analysis were 
performed as described in detail elsewhere.
12 
Brieﬂ  y, image capture and signal quantiﬁ  cation of 
hybridized PIQOR
TM microarrays were per-
formed with the ScanArraylite (Packard Bioscience, 
Billerica, MA, U.S.A) and ImaGene software 
Version 4.1 (BioDiscovery, Los Angeles, CA, 
U.S.A). Local background was subtracted from the 
signal to obtain the net signal intensity and the ratio 
of Cy5/Cy3. Subsequently, the mean of the ratios 
of four corresponding spots representing the same 
cDNA was computed. For normalization, only the 
spots for which the ﬂ  uorescent intensity in one of 
the two channels was at least two times the mean 
background intensity of all unﬂ  agged spots was 
used. Only the genes displaying a net signal inten-
sity two-fold higher than the mean background 
were used for further analysis.
Identiﬁ  cation of differentially 
expressed genes
As a rule of thumb, changes in expression in the 
PIQOR microarray experiments of more than two-
fold are considered to be reliable and signiﬁ  cant. 
Thus, all genes in our lists were with log 2 ratio 
values equal and above 1.0 and equal and lower 
than −1.0. The various lists were compared and 
genes which appeared on all the compared lists were 
compiled in new sublists. This provided a condensed 
list of genes that contain only those genes differen-
tially expressed in all the analysed samples.
Pathway analysis of the common 
differentially expressed genes
Pathway analysis means the analysis of relation-
ships between genes or proteins and the processes 
or diseases in which these genes or proteins are 
involved. In order to get an idea about the biological 
meaning of the differential expression of the com-
mon up- and downregulated genes, differentially 
expressed genes were subjected to biological path-
way analysis.
Interactions with ﬁ  brillin-1 using 
a MedScan search and pathway
assist software
A MedScan search was performed and followed 
by using PathwayAssist software (www.
ariadnegenomics.com) to look for interactors of 
ﬁ  brillin 1 gene. This software automatically screens 
databases of scientiﬁ  c abstracts via the Internet and 
collects recognized biological terms, matching and 
ﬁ  ltering them in reference to the user’s input. The 
software deﬁ  nes descriptions of sorted gene/protein 
functions and interactions, regulatory events, bio-
chemical cellular pathways and links between 
them. It provides a built-in database, containing 
thousands of events of regulation, interaction and 
modiﬁ  cation between proteins, cell processes and 84
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small molecules, compiled by the application of 
text- and data-mining software to PubMed. This 
tool assists users to deﬁ  ne the common regulators 
and targets of differentially expressed genes.
Validation of the common differentially 
expressed genes using qRT-PCR 
and protein analysis
Validation using qRT-PCR of 30 genes was 
undertaken for all of the 33 patients in this study. 
Total RNA was prepared using RNeasy
TM Total 
RNA Kit (Qiagen, Hilden, Germany). Primers are 
listed in Table 2; run conditions and measurement 
have been described previously.
17 For protein 
analysis, 100 mg of tissue were homogenized in 
500 μl lysis buffer. SDS-PAGE (10%) and trans-
ferred to a nitrocellulose membrane for Western 
blot analysis according to the manufacturer’s 
instructions (Amersham Pharmacia). The polypep-
tide bands were semi-quantiﬁ  ed using computerized 
blot scanning; the optical density of every sample 
Table 2. Primer sequences.
Gene
symbol
Forward primer Reverse primer Fragment 
size (bp)
FBLN1 TCA TCT CGC TGC CTA CCT TC CCG TCC ATG TAA CGC TTG AT 163
FBLN2 TCA CGC ACT ACC AGC TCA AC CTG CCT CCA GAG CTT CAT CT 239
DCN ATG TGT CTA CGT GCG CTC TG CTG AAA ATG GCA GGC AAA AT 241
MMP19 ACA GCC CTT CCA ACT GTG TC TGC CCG TAA TCA TAA GCA CA 166
IL6 TAC CCC CAG GAG AAG ATT C TTT TCT GCC AGT GCC TCT TT 175
CCL2 TCC CCA GAC ACC CTG TTT TA CAA AAC ATC CCA GGG GTA GA 199
MFAP5 GCT TCA CCA GTT TAC GAC GTA TG ACA GGG AGG AAG TCG GAA GT 161
MFAP2 TCC TGT GCC AGG AGC TG GGG CTG CAG TCC ACT AAC TT 157
EGR1 CTG GTG GAG ACC AGT TAC CC TGG GTT GGT CAT GCT CAC TA 156
ITGB4 GCC TTC ACT TTG AGC ACT CC ACT TGT AGG GCA CGT TCT CG 238
THBD ACA TCG ACG AGT GCG AAA AC GGA GAT GCC TAT GAG CAA GC 245
ITGA5 AAG CCC TGA AGA TGC CCT AC GGA GCG TTT GAA GAA TCC AA 203
TGFB1 CAA CAA TTC CTG GCG ATA CC GAA CCC GTT GAT GTC CAC TT 193
CCL13 GCT GGC AGT GGG TTT GTA TT TTG CAT TCA TCT TTC CAC AA 152
CXCL14 GGT CCA AAT GCA AGT GCT C CAG TGC TCC TGA CCT CGG TA 151
CCL14 CAA CCC CAG TGA CAA GTG G AAG CTC CAA GAG GGT GAC TG 166
CCL15 CAC ATC CCA ATC CTG AAT CC CAA GGC TGA GAG TGC AAC AG 205
PRG4 TGC CAG AAT TGA ACC CTA CC CTT CAG GCA TGA ACA CAT GG 177
TGFBR2 CTA ACC TGC TGC CTG TGT GA TCG GTC TGC TTG AAG GAC TC 167
MMP9 GGG AAG ATG CTG CTG TTC A TCA ACT CAC TCC GGG AAC TC 202
GEM ATG CAG CCA CAG CAG CAG GTC TGT GGA GTC AGA GGA CCA 150
SFRP2 GCC TCG ATG ACC TAG ACG AG GAT GCA AAG GTC GTT GTC CT 152
COL1A1 CAG GAA TTC GGC TTC GAC CCA TGT GAA ATT GTC TCC CAT T 164
COL11A1 CAC ATG GCA AAA GCT TTG AA TGG ATG GAT GAG AAT GAG CA 185
COL15A1 TGA ACC TCA AGG GCC AAG TA TTC GCC ATG CTT CAC AGT AG 204
COL3A1 AAA GAC GCA TGT TAT GGT GCT CAG GAT GAA GGA GGA GAA TCC 155
COL1A2 CAC CAC TTG TGG CTT TTG AA CAA AAC AAG GAC CTC AGT TCA TC 151
HMOX1 ATG ACA CCA AGG ACC AGA GC GTG TAA GGA CCC ATC GGA GA 153
JUNB ACC CCT ACC GGA GTC TCA AA GTT GCT GTT GGG GAC AAT CA 155
THBS4 TAT CGC TGC AAT GAC ACC AT TTG CCA CAT TCA CAT AAA ACG 19485
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was estimated after the normalization to anti beta 
Actin (Acris Antibodies GmbH, Hidenhausen, 
Germany) and compared to control sample using 
ImageJ (http://rsb.info.nih.gov/ij/).
Statistics
All data are presented as mean  ±  SD. Comparison 
was made between type A (acute dissection) versus 
Marfan syndrome and between Marfan syndrome 
versus control using standard Student’s t-test. 
Differences among groups were assumed signiﬁ  -
cant at p values  0.05.
Results
Inter-experiment correlation analysis
The global expression proﬁ  les of microarrays were 
compared in a correlation analysis; the obtained 
inter-experiment correlation coefficients were 
listed. The various experiments were plotted 
against each other in scatter diagrams to visualize 
the correlation between the samples, followed by 
a graphical representation of the correlation values. 
Figure 1 demonstrated the results of ﬁ  ve microar-
rays (AAD versus MS). Positive correlations are 
shown in shades of yellow (more intensive colour = 
better correlation), while anti-correlations are 
indicated by shades of blue.
Identiﬁ  cation of differentially 
expressed genes
Genes with more than a two-fold change in expres-
sion in the PIQOR microarray experiments were 
considered to be reliable and significant, and 
divided according to their functions in lists. The 
different lists were compared, and genes which 
appeared in all of the compared lists were compiled 
into new sublists. A condensed list of 16 genes 
(Table 3) was created containing only those genes 
which were differentially expressed in all the 
analysed samples.
In an additional approach, the mean values of 
the expression values of all the genes were calcu-
lated and those with an at least two-fold up- 
or downregulation were extracted to a new list. 
This method is less stringent and allows genes with 
missing expression values for one or more exper-
iments to be considered for later pathway analysis. 
The list obtained with the latter method contained 
88 genes, generated from the medians of the gene 
expression, which were clustered according to their 
biological annotations. A group of 32 genes with 
high signiﬁ  cance, involved in extracellular matrix 
assembly and in extracellular space building was 
identiﬁ  ed (shown in Table 4). The expression of 
genes with high signiﬁ  cance was validated in qRT-
PCR with primers listed in Table 2, and then protein 
analysis was performed.
Pathway analysis of the common 
differentially expressed genes
The genes which were differentially expressed in 
all analysed samples (listed in Table 4) were sub-
jected to biological pathway analysis, revealing 
another major group (clusters). A closer look at 
these clusters revealed proteins involved in extra-
cellular matrix assembly or maintenance as well 
as cell adhesion and signalling.
A number of matrix metalloproteases (MMP-19, 
MMP-12, MMP-9) were differentially expressed 
in tissues obtained from patients with AAD. 
X3970160
X
3
9
7
0
1
6
0
X3970161
X
3
9
7
0
1
6
1
X3970162
X
3
9
7
0
1
6
2
X3970163
X
3
9
7
0
1
6
3
X3710104
X
3
7
1
0
1
0
4
–1.0.01.0
Figure 1. Global inter-experiment correlations analysis. Representa-
tively, detection of gene expression: lanes with the initials X3970160, 
X3970161, X3970162, X3970163 demonstrated the detection of gene 
expression on microarray, RNA obtained from four samples of AAD 
tissue hybridized against RNA obtained from MS tissue. In lane 
X3710104 pooled RNA of eight patients with AAD is shown.86
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MMP-19 was the only matrix metalloprotease 
being upregulated, while MMP-12 and MMP-9 
were downregulated. Furthermore, the expression 
levels of some collagens were reduced (COL11A1, 
COL1A1, COL3A1, COL1A2, COL15A1). Among 
the seven chemokines which were differentially 
expressed in the microarrays, six were downregu-
lated in their expression. Only CCL2 was upregu-
lated by a factor of 2 to 3 in four of the five 
microarrays. The other chemokines (CCL13, 
CCL14, CCL15, CXCL14, CCL21 and CCL19) 
were all downregulated in the analysed samples. In 
addition, IL6 was upregulated.
Interactions with ﬁ  brillin-1 (FBN1)
Interactors of FBN1 revealed by a MedScan search 
using InteractionExplorer software PathwayAssist 
showed four genes (ﬁ  bulin-1 (FBLN1), ﬁ  bulin-2 
(FBLN2), decorin (DCN) and microﬁ  brillar asso-
ciated protein 5 (MFAP5)), which were differen-
tially expressed in all AAD patients included in the 
analysis (Fig. 2).
We used the InteractionExplorer software again 
to check all the differentially expressed genes for 
further analysis to study interactions and molecu-
lar networks. Among the regulators of the differ-
entially expressed genes certain growth factors 
were identiﬁ  ed; PGF, EGF, TGFB1, HGF and 
platelet-derived growth factor.
Validation of the common differentially 
expressed genes using qRT-PCR 
and protein analysis
qRT-PCR, after three repeats, revealed a minimum 
three-fold downregulation of FBLN1 (0.5 ± 0.4 vs. 
6.1 ± 2.3 fold, p = 0.003) and of DCN (2.5 ± 1.0 vs. 
8.5 ± 4.7 fold, p = 0.04) in AAD compared to MS and 
control samples. Representatively, validation of the 
four interactions of FBN1 is shown in Figure 3A. 
The average of FBLN1 protein in all investigated 
AAD samples after the normalization to Actin and 
semi-quantified, showed 30% downregulation 
(p   0.02), Figure 3B demonstrates the detec-
tion of FBLN1 protein in eight representative 
samples.
Discussion
Despite its high mortality rate, acute aortic 
dissection (AAD) presents a relatively unclariﬁ  ed 
entity of the arterial system. It was ﬁ  rst described 
in the eighteenth century during autopsy by 
Dr. Nicholls, physician to King George II.
18 Even 
today AAD remains a disease with high mortality 
rates, with about 2000 new cases in North America 
and 3000 new cases in Europe every year. 
It requires urgent clinical intervention; untreated 
cases have a mortality rate reaching about 
36%–72% within the ﬁ  rst 48 hours (classiﬁ  cation 
after Stanford type A).
9
In their study Weis-Müller et al described the 
molecular features underlying the pathogenesis 
of AAD as obscure.
10 They compared tissue from 
dissected aorta with normal aortic tissue using 
microarrays and found some indications of AAD 
Table 3. List of 16 condensed genes which are 
differentially expressed in all patient samples, including 
the pool of RNA obtained from eight AAD patients.
Name of the most 
upregulated genes
Median expression
Early growth response 1 2.87
Interleukin 6 1.32
Integrin, alpha 5 2.11
Jun B proto-oncogene 1.89
Chemokine (C-C motif)
ligand 2
2.49
FBJ murine osteosarcoma
viral oncogene homolog B
1.84
Matrix metalloproteinase 19 1.96
Name of the most
downregulated genes
Fibulin 1 −2.56
Decorin −3.47
Fibulin 2 −0.32
Thrombospondin 4 −2.18
Proteoglycan 4 −1.89
Microﬁ  brillar associated
protein 5
−0.28
Chemokine (C-X-C motif) 
ligand 14
−2.74
Secreted frizzled-related 
protein 2
−2.18
Chemokine (C-C motif) 
ligand 13
−2.47
Small inducible cytokine b14 
precursor
−2.74
Chemokine (C-C motif) 
ligand 15
−3.0687
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differentially expressed genes;
19 however, the 
pathway of these differentially expressed genes 
is still to be deﬁ  ned. Also, the underlying mecha-
nisms which make the aorta more prone to be 
dissected remain unclariﬁ  ed. In this study we 
investigated whether dissected aortic tissues 
present significant similarities in their gene 
expression pattern. We generated 88 differentially 
expressed genes in tissue obtained from patients 
with AAD compared with MS by using microar-
rays, and clustered them according to their bio-
logical annotation. We found that most of the 
genes identiﬁ  ed as differentially expressed are 
assigned to ‘extracellular space’. Examination of 
these clusters revealed proteins involved in extra-
cellular matrix assembly or maintenance, as well 
as cell adhesion and signalling.
A number of matrix metalloproteases (MMP-19, 
MMP-12, MMP-9) was differentially expressed in 
AAD patients. MMP-19 was upregulated and 
MMP-12 and MMP-9 were downregulated. The 
expression levels of some collagens were reduced 
(COL11A1, COL1A1, COL3A1, COL1A2, 
COL15A1). Our results suggest that the extracel-
lular matrix was weakened and cell adhesion might 
be reduced in affected patients.
Seven chemokines were identiﬁ  ed; six were 
downregulated in their expression. Only CCL2 was 
upregulated, by a factor of 2 to 3. CCL2, a potent 
leukocyte chemoattractant, is known to induce 
macrophage recruitment and activation involved 
in diseases such as psoriasis, rheumatoid arthritis 
and arteriosclerosis.
20–22 In addition, IL6 was 
upregulated, indicating that the tissues of the 
affected patients presented an inflammatory 
response in AAD. Another interesting gene that we 
found (data published elsewhere) with high 
expressed in AAD (not included in the PIQOR 
microarray) is the high mobility group AT-hook 2 
(HMGA2).
The investigated AAD patients presented 
neither clinical manifestation nor mutations of 
Fibrillin-1 gene, however, expression levels of 
Fibrillin 1 gene and its interaction partners in 
AAD samples are of interest. A reduced expres-
sion of Fibrillin-1 and its interaction partners 
could be an alternative molecular mechanism 
leading to AAD phenotype. It is known that ﬁ  bril-
lin-1 protein can bind ﬁ  bulin-1 and -2 as well as 
decorin. Downregulation of ﬁ  bulin-1 gene in 
AAD corresponds with its possible impact on 
this disease. Fibulin-1 is an essential component 
of vascular basement membrane, ﬁ  bulin-1 knock-
out mice die soon after birth due to massive 
bleeding from small sized vessels.
23 At the same 
time, there is evidence about a regulatory function 
Table 4. A sublist of 32 genes was created from genes, 
whose median values were signiﬁ  cant and above the 
threshold of two-fold regulation. These genes are 
clustering in a group assigned to ‘extracellular space.’ 
Nine genes, identical to those represented in Table 3, 
are marked in cursive.
Name Description
C2 complement component 2
PMP22 peripheral myelin protein 22
SDC1 syndecan 1
COL11A1 collagen, type XI, alpha 1
ITGB4 integrin, beta 4
DCN decorin
THBS4 thrombospondin 4
COL1A1 collagen, type I, alpha 1
IFIT1 interferon-induced protein with 
tetratricopeptide repeats 1
LUM lumican
MMP9 matrix metalloproteinase 9
COL3A1 collagen, type III, alpha 1
COL1A2 collagen, type I, alpha 2
JAK1 Janus kinase 1
MMP12 matrix metalloproteinase 12
TNFSF10 tumour necrosis factor (ligand) 
superfamily, member 10
HSPA4 heat shock 70 kDa protein 4
FBLN2 ﬁ  bulin 2
SFRP2 secreted frizzled-related protein 2
COL15A1 collagen, type XV, alpha 1
FBLN1 ﬁ  bulin-1
GEM GTP binding protein
MATN2 matrilin 2
CCL21 chemokine (C-C motif) ligand 21
CCL19 chemokine (C-C motif) ligand 19
SLCO2A1 solute carrier organic anion transporter 
family, member 2A1
MFAP5 microﬁ  brillar-associated protein 5
CXCL14 chemokine (C-X-C motif) ligand 14
PRG4 proteoglycan 4
CCL13 chemokine (C-C motif) ligand 13
CCL14 chemokine (C-C motif) ligand 14
CCL15 chemokine (C-C motif) ligand 1588
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Figure 2. Interactors of FBN1 found by a MedScan search using PathwayAssist software.The genes coding for the proteins with the green 
halos were differentially expressed in the current microarray experiment.
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Figure 3. Validation of four differentially expressed genes using qRT-PCR is presented in 3A; those four genes are directly interact in the 
pathway analysis with FBN1. They are involved in ECM development. Representatively, in 3B) a Western blot demonstrated detection of 
ﬁ  bulin-1 protein in tissue obtained from Marfan syndrome (34), in six different patients with AAD (HB54,-55,-56,-57,-69 and HB68) and in 
control (39).89
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of fibulin, as it inhibits the activity of the 
extracellular signal-regulated kinase, and thus 
the signal transduction.
24 An altered Fibulin-1 
gene expression might be a decisive factor in the 
formation of aortic dissection in Patients without 
Marfan-Syndrome.
Therefore, a downregulation of fibulin-1 
expression may contribute to the development 
of aortic dissection, either by weakening the 
aortic connective tissue or by altering the cel-
lular signal transduction. Decorin is considered 
as another candidate gene for Marfan syndrome.
25 
It is interesting to see ﬁ  bulin-2 is upregulated in 
AAD. The upregulation expression of ﬁ  bulin-2 
is in AAD probably due to multiple different 
reasons (inﬂ  ammation, hemodynamic effects-
high blood pressure, etc.). Low expression levels 
of decorin may lead to restriction in the ability 
to assemble extracellular matrix and to build up 
connective tissue in the aorta, with the conse-
quence of presenting the AAD phenotype. We 
conclude that the downregulation of ﬁ  bulin-1 
and/or of decorin in AAD patients could be an 
alternative molecular mechanism—opposed to a 
mutation in ﬁ  brillin-1 as seen in patients suffer-
ing from Marfan syndrome—leading to the same 
or similar phenotype. Further studies of decorin, 
ﬁ  bulin-1, and others like HMGA2 may prove 
their role and how they may develop the symp-
toms of AAD. Since a clinical test to detect AAD 
on a daily basis is still lacking,
26 these results 
may increase our understanding of the molecular 
mechanisms underlying AAD, and thus may 
support the future development of a panel of 
markers as a clinical test for monitoring patients 
at high risk.
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